Abstract
No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment
Journal of clinical oncology, Vol.37(15_suppl), pp.3073-3073
05/20/2019
DOI: 10.1200/JCO.2019.37.15_suppl.3073
Abstract
Abstract only
3073
Background: Widespread integration of systematized next generation sequencing (NGS)-based precision oncology is hindered by numerous barriers. Hence, we developed the Strata trial (NCT03061305), a screening protocol to determine the impact of scaled precision oncology. Methods: We implemented no-cost NGS on formalin fixed paraffin embedded (FFPE) clinical samples for all patients with advanced tumors, a common portfolio of partnered therapeutic clinical trials, and robust infrastructure development across the Strata Precision Oncology Network. Results: Across the network of 17 centers, specimens from 8673/9222 (94%) patients were successfully tested in the Strata CLIA/CAP/NCI-MATCH accredited laboratory using comprehensive amplicon-based DNA and RNA NGS. Patients were tested with one of three StrataNGS test versions; the most recent panel assesses all classes of actionable alterations (mutations, copy number alterations, gene fusions, microsatellite instability, tumor mutation burden and PD-L1 expression). Median surface area of received FFPE tumor samples was 25mm
2
(interquartile range 9-95mm
2
), and the median turnaround time from sample receipt to report was 6 business days. 2577 (27.9%) patients had highly actionable alterations, defined as alterations associated with within-cancer type FDA approved or NCCN guideline recommended therapies (1072 patients), NCI-MATCH trial arms (1467 patients), Strata-partnered therapeutic trials (327 patients), or specific alteration-matched FDA approved therapies in patients with cancers of unknown primary (71 patients). Of the 1467 patients matched to an NCI-MATCH trial arm, 15 enrolled. Of the 327 patients matched to one of nine Strata-partnered clinical trials, 77 (24%) were screen failures, while 250 (76%) have either enrolled or are being actively followed for enrollment upon progression. Conclusions: Through streamlined consent methods, electronic medical record queries, and high throughput laboratory testing at no cost to patients, we demonstrate that scaled precision oncology is feasible across a diverse network of healthcare systems when paired with access to relevant clinical trials. Clinical trial information: NCT03061305.
Details
- Title: Subtitle
- No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment
- Creators
- Marc Ryan Matrana - Ochsner Medical CenterScott A. Tomlins - Strata Oncology, Ann Arbor, MIKat Kwiatkowski - Strata Oncology, Ann Arbor, MIKhalis Mitchell - Strata Oncology, Ann Arbor, MIJennifer Marie Suga - Kaiser Permanente Vallejo Medical CenterElizabeth Claire Dees - University of North Carolina at Chapel HillMark E. Burkard - University of Wisconsin Carbone Cancer CenterJamil Khatri - Christiana Care Health SystemMalek M. Safa - Kettering Medical CenterEddy Shih-Hsin Yang - University of Alabama at BirminghamBenjamin Parsons - Gundersen Health SystemAlex R. Menter - Kaiser PermanenteMichael A. Thompson - Aurora Health CareAnneliese O Gonzalez - The University of Texas Health Science Center at HoustonTimothy Robert Wassenaar - ProHealth CareDan Rhodes - Strata Oncology, Ann Arbor, NC
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.37(15_suppl), pp.3073-3073
- Publisher
- AMER SOC CLINICAL ONCOLOGY; ALEXANDRIA
- DOI
- 10.1200/JCO.2019.37.15_suppl.3073
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2019
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984700648402771
Metrics
4 Record Views